Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bostwick Therapeutics has received clearance from the FDA and the Institutional Review Board of Community Memorial Hospital, Ventura, California, to initiate the Critical trial, a clinical trial examining the potential of a novel combination of cryoablation and intra-tumoral injection of 'virgin' dendritic cells to treat men with metastatic androgen-independent prostate cancer.
Subscribe to our email newsletter
Cryoablation of cancer in the prostate will employ technology provided by Endocare, Irvine, California. Virgin dendritic cells (VDC2008) consist of each patient’s own immature dendritic cells obtained from blood-borne precursors and introduced back to the individual.
Dendritic cells are said to be capable of triggering a highly specific immune response against antigenic targets systemically. According to the company, cryoablation of cancer releases numerous antigens, and intratumoral injection of VDC2008 into this antigen-rich environment may result in targeted immune-mediated destruction of cancer metastases.
Duke Bahn, investigator of the study, said: “Through the application of VDC2008, we will attempt to leverage this potential by combining cancer ablation with immune-activating therapy.”